BRISTOL-MYERS SQUIBB COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.08 USD | +0.30% |
|
+2.71% | -12.12% |
| May. 10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
| May. 10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Other Pharmaceuticals | +0.32% | +2.71% | -12.12% | -33.86% | -1.76% | 91.1B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- BMY Stock
- Charts Bristol-Myers Squibb Company
- Comparison Chart
